+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Oxidative stress and inflammation in mucopolysaccharidosis type IVA patients treated with enzyme replacement therapy



Oxidative stress and inflammation in mucopolysaccharidosis type IVA patients treated with enzyme replacement therapy



Biochimica et Biophysica Acta 1852(5): 1012-1019



Mucopolysaccharidosis type IVA (MPS IVA) is an inborn error of glycosaminoglycan (GAG) catabolism due to the deficient activity of N-acetylgalactosamine-6-sulfate sulfatase that leads to accumulation of the keratan sulfate and chondroitin 6-sulfate in body fluids and in lysosomes. The pathophysiology of this lysosomal storage disorder is not completely understood. The aim of this study was to investigate oxidative stress parameters, pro-inflammatory cytokine and GAG levels in MPS IVA patients. We analyzed urine and blood samples from patients under ERT (n=17) and healthy age-matched controls (n=10-15). Patients presented a reduction of antioxidant defense levels, assessed by a decrease in glutathione content and by an increase in superoxide dismutase activity in erythrocytes. Concerning lipid and protein damage, it was verified increased urine isoprostanes and di-tyrosine levels and decreased plasma sulfhydryl groups in MPS IVA patients compared to controls. MPS IVA patients showed higher DNA damage than control group and this damage had an oxidative origin in both pyrimidine and purine bases. Interleukin 6 was increased in patients and presented an inverse correlation with GSH levels, showing a possible link between inflammation and oxidative stress in MPS IVA disease. The data presented suggest that pro-inflammatory and pro-oxidant states occur in MPS IVA patients even under ERT. Taking these results into account, supplementation of antioxidants in combination with ERT can be a tentative therapeutic approach with the purpose of improving the patient's quality of life. To the best of our knowledge, this is the first study relating MPS IVA patients with oxidative stress.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 058488932

Download citation: RISBibTeXText

PMID: 25701642

DOI: 10.1016/j.bbadis.2015.02.004


Related references

Oxidative stress in patients with mucopolysaccharidosis type II before and during enzyme replacement therapy. Molecular Genetics and Metabolism 103(2): 121-127, 2011

Mutational and oxidative stress analysis in patients with mucopolysaccharidosis type I undergoing enzyme replacement therapy. Clinica Chimica Acta; International Journal of Clinical Chemistry 387(1-2): 75-79, 2007

Oxidative and nitrative stress and pro-inflammatory cytokines in Mucopolysaccharidosis type II patients: effect of long-term enzyme replacement therapy and relation with glycosaminoglycan accumulation. Biochimica et Biophysica Acta 1862(9): 1608-1616, 2016

Globotriaosylceramide is correlated with oxidative stress and inflammation in Fabry patients treated with enzyme replacement therapy. Biochimica et Biophysica Acta 1822(2): 226-232, 2012

Glycosaminoglycans can be associated with oxidative damage in mucopolysaccharidosis II patients submitted to enzyme replacement therapy. Cell Biology and Toxicology 30(4): 189-193, 2015

Evaluation of motor response in mucopolysaccharidosis patients treated with enzyme replacement therapy. Ortopedia, Traumatologia, Rehabilitacja 15(5): 389-393, 2015

Enzyme replacement therapy with idursulfase in patients with mucopolysaccharidosis type II. Acta Paediatrica 97(457): 76-78, 2008

Enzyme replacement therapy for Mucopolysaccharidosis Type I among patients followed within the MPS Brazil Network. Genetics and Molecular Biology 37(1): 23-29, 2014

Effects of enzyme replacement therapy on growth in patients with mucopolysaccharidosis type II. Journal of Inherited Metabolic Disease 34(1): 203-208, 2011

Mutational analysis of mucopolysaccharidosis type VI patients undergoing a trial of enzyme replacement therapy. Human Mutation 23(3): 229-233, 2004

Enzyme replacement in murine mucopolysaccharidosis type VII: neuronal and glial response to beta-glucuronidase requires early initiation of enzyme replacement therapy. Pediatric Research 45(6): 838-844, 1999

Enzyme replacement therapy for mucopolysaccharidosis VI: Growth and pubertal development in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase. Journal of Pediatric Rehabilitation Medicine 3(2): 89-100, 2010

Mutational analysis of mucopolysaccharidosis type VI patients undergoing a phase II trial of enzyme replacement therapy. Molecular Genetics and Metabolism 90(2): 164-170, 2006

DNA damage in leukocytes from pretreatment mucopolysaccharidosis type II patients; protective effect of enzyme replacement therapy. Mutation Research 721(2): 206-210, 2011

Enzyme replacement therapy improves joint motion and outcome of the 12-min walk test in a mucopolysaccharidosis type VI patient previously treated with bone marrow transplantation. American Journal of Medical Genetics. Part A 158a(5): 1158-1163, 2012